Fig. 3From: Cost-effectiveness of empagliflozin in patients with type 2 diabetes and established cardiovascular disease in ChinaCost-effectiveness scatter plot of empagliflozin + SoC versus sitagliptin + SoC and liraglutide + SoC (in terms of QALYs). Empa empagliflozin, Lira liraglutide, QALE quality-adjusted life expectancy, QALY quality-adjusted life-year, Sita sitagliptin, SoC standard of careBack to article page